Check a new immunotherapy with chemo for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 study tests whether adding envafolimab (an immunotherapy) to docetaxel—sometimes with another drug—can improve outcomes in advanced non-small cell lung cancer (NSCLC). It focuses on people whose cancer has already gotten worse after platinum chemotherapy plus a PD-1–based treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have advanced or metastatic NSCLC confirmed by tissue testing
- Your cancer has progressed after platinum chemotherapy plus a PD-1 inhibitor
- Your cancer can be measured on scans (at least one measurable spot on RECIST 1.1)
- Your brain metastases are either not causing symptoms or are stable after treatment
- Your overall health score (ECOG) is 0 to 1, and you expect to live more than 12 weeks
- Recent blood tests and organ function meet the lab thresholds (for blood counts, kidney, liver, and protein levels)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug combination (trilaciclib plus docetaxel) for people with advanced lung cancer (NSCLC) whose cancer has progressed after at least one prior treatment. The goal is to see if adding trilaciclib helps the chemotherapy work better with fewer side effects.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a combination of four drugs as a first treatment for people with extensive-stage small cell lung cancer. The goal is to see if the combination is safe and effective. It may be an option for those who have not had prior treatment for advanced disease.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
Hear when a new Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.